$7.50
6.13% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US81750R1023
Symbol
MCRB
Sector
Industry

Seres Therapeutics Inc Stock price

$7.50
+0.13 1.76% 1M
-10.07 57.32% 6M
-9.12 54.87% YTD
-6.71 47.21% 1Y
-83.90 91.79% 5Y
-1,020.50 99.27% 10Y
-1,020.50 99.27% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.49 6.13%
ISIN
US81750R1023
Symbol
MCRB
Sector
Industry

Key metrics

Market capitalization $69.77m
Enterprise Value $10.92m
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.38
Free Cash Flow (TTM) Free Cash Flow $-86.81m
Cash position $58.85m
P/E forward negative
Short interest 13.26%

Is Seres Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Seres Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Seres Therapeutics Inc forecast:

2x Buy
40%
2x Hold
40%
1x Sell
20%

Analyst Opinions

5 Analysts have issued a Seres Therapeutics Inc forecast:

Buy
40%
Hold
40%
Sell
20%

Financial data from Seres Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 56 56
33% 33%
-
- Research and Development Expense 66 66
52% 52%
-
-120 -120
25% 25%
-
- Depreciation and Amortization 5.47 5.47
12% 12%
-
EBIT (Operating Income) EBIT -126 -126
22% 22%
-
Net Profit 0.14 0.14
100% 100%
-

In millions USD.

Don't miss a Thing! We will send you all news about Seres Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Seres Therapeutics Inc Stock News

Neutral
GlobeNewsWire
18 days ago
Results highlight potential role of SER-155 in promoting peripheral T-cell recovery and immune reconstitution to support favorable outcomes post allogeneic hematopoietic stem cell transplant (allo-HSCT) Results highlight potential role of SER-155 in promoting peripheral T-cell recovery and immune reconstitution to support favorable outcomes post allogeneic hematopoietic stem cell transplant (al...
Neutral
Seeking Alpha
about one month ago
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q1 2025 Earnings Call May 7, 2025 8:30 AM ET Company Participants Carlo Tanzi - Investor Relations Eric Shaff - President and Chief Executive Officer Marella Thorell - Chief Financial Officer Matthew Henn - Chief Scientific Officer Terri Young - Chief Commercial and Strategy Officer Dennis Walling - Senior Vice President, Clinical Development Conference C...
Neutral
GlobeNewsWire
about one month ago
In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce int...
More Seres Therapeutics Inc News

Company Profile

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Head office United States
CEO Eric Shaff
Employees 103
Founded 2010
Website www.serestherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today